{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:00:33Z","timestamp":1790708433553,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,8]]},"DOI":"10.1097\/jcp.0b013e31817ef470","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T19:52:39Z","timestamp":1236282759000},"page":"432-440","source":"Crossref","is-referenced-by-count":63,"title":["Physiological and Subjective Responses to Controlled Oral 3,4-Methylenedioxymethamphetamine Administration"],"prefix":"10.1097","volume":"28","author":[{"given":"Erin A.","family":"Kolbrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gorelick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn A.","family":"Huestis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","article-title":"Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.","volume":"26","author":"de la Torre","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R2-11-20210128","first-page":"727","article-title":"Recreational drugs: current trends in the 90s.","volume":"18","author":"Ropero-Miller","year":"1998","journal-title":"Toxicology"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting.","volume":"18","author":"Greer","year":"1986","journal-title":"J Psychoactive Drugs"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/bja\/ael078","article-title":"Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management.","volume":"96","author":"Hall","year":"2006","journal-title":"Br J Anaesth"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/0003-4819-133-12-200012190-00012","article-title":"Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial.","volume":"133","author":"Lester","year":"2000","journal-title":"Ann Intern Med"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.npp.1395197","article-title":"Psychological and cardiovascular effects and short-term sequelae of MDMA (\"ecstasy\") in MDMA-naive healthy volunteers.","volume":"19","author":"Vollenweider","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00213-002-1131-1","article-title":"Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"162","author":"Harris","year":"2002","journal-title":"Psychopharmacology"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1749-6632.2000.tb05199.x","article-title":"Pharmacology of MDMA in humans.","volume":"914","author":"de la Torre","year":"2000","journal-title":"Ann NY Acad Sci"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/02791072.1986.10472366","article-title":"The psychological and physiological effects of MDMA on normal volunteers.","volume":"18","author":"Downing","year":"1986","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","article-title":"Human pharmacology of 3,4-methylenedioxymethamphetamine (\"ecstasy\"): psychomotor performance and subjective effects.","volume":"20","author":"Cami","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002130000648","article-title":"Gender differences in the subjective effects of MDMA.","volume":"154","author":"Liechti","year":"2001","journal-title":"Psychopharmacology"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/02791072.1986.10472368","article-title":"MDMA. Nonmedical use and intoxication.","volume":"18","author":"Siegel","year":"1986","journal-title":"J Psychoactive Drugs"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00007691-200204000-00009","article-title":"Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives.","volume":"24","author":"Kraemer","year":"2002","journal-title":"Ther Drug Monit"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1021\/tx010051p","article-title":"3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans.","volume":"14","author":"Segura","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-2125.2000.00121.x","article-title":"Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.","volume":"49","author":"de la Torre","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0378-4347(98)00506-4","article-title":"Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection.","volume":"723","author":"Ortuno","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/clinchem\/45.7.1058","article-title":"Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (ecstasy) in humans.","volume":"45","author":"Fallon","year":"1999","journal-title":"Clin Chem"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0022-3565(24)34877-3","article-title":"Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans.","volume":"290","author":"Mas","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1093\/clinchem\/47.10.1788","article-title":"Usefulness of saliva for measurement of 3,4-methylenedioxymehamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH.","volume":"47","author":"Navarro","year":"2001","journal-title":"Clin Chem"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/FTD.0b013e3181684fa0","article-title":"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.","volume":"30","author":"Kolbrich","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0378-4274(99)00207-6","article-title":"Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('ecstasy').","volume":"112-","author":"Maurer","year":"2000","journal-title":"Toxicol Lett"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1373\/clinchem.2007.096800","article-title":"Two-dimensional gas chromatography\/electron impact-mass spectrometry with cryofocusing for the sensitive, specific and simultaneous quantification of 3,4-methylenedioxymethamphetamine (MDMA, 3,4-methylenedioxyampheta\\mine (MDA), 4-hydroxy-3-methoxymethamphetamine (HMMA), 4-hydroxy-3-methoxyamphetamine (HMA), and 3,4-methylenedioxyethylamphetamine (MDEA) in human plasma.","volume":"54","author":"Kolbrich","year":"2008","journal-title":"Clin Chem"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.107.129056","article-title":"Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.","volume":"323","author":"Farre","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00213-004-1789-7","article-title":"Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics.","volume":"173","author":"Farre","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.resuscitation.2005.01.020","article-title":"Methylenedioxymethamphetamine (ecstasy)-related myocardial hypertrophy: an autopsy study.","volume":"66","author":"Patel","year":"2005","journal-title":"Resuscitation"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/026988110001400313","article-title":"The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (\"ecstasy\") in healthy volunteers.","volume":"14","author":"Liechti","year":"2000","journal-title":"J Psychopharmacol"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0269881106063268","article-title":"MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.","volume":"20","author":"Parrott","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ajem.2004.04.022","article-title":"Ecstasy overdose: rapid cooling leads to successful outcome.","volume":"22","author":"Bordo","year":"2004","journal-title":"Am J Emerg Med"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1520\/JFS15211J","article-title":"Ecstasy (MDMA) deaths in New York City: a case series and review of the literature.","volume":"47","author":"Gill","year":"2002","journal-title":"J Forensic Sci"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-O","article-title":"Toxicity and deaths from 3,4-methylenedioxymethamphetamine (\"ecstasy\").","volume":"340","author":"Henry","year":"1992","journal-title":"Lancet"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00213-005-0149-6","article-title":"Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"183","author":"Freedman","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1152\/japplphysiol.01064.2005","article-title":"Neuronal basis of Hammel's model for set-point thermoregulation.","volume":"100","author":"Boulant","year":"2006","journal-title":"J Appl Physiol"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/bjo.87.11.1387","article-title":"Pupil dilatation does affect some aspects of daytime driving performance.","volume":"87","author":"Wood","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1124\/jpet.300.1.236","article-title":"3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.","volume":"300","author":"Hernandez-Lopez","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(01)00146-6","article-title":"The subjective effects of MDMA and mCPP in moderate MDMA users.","volume":"65","author":"Tancer","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","article-title":"The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans.","volume":"189","author":"Tancer","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R38-11-20210128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0379-0738(96)02025-7","article-title":"Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning.","volume":"83","author":"Moore","year":"1996","journal-title":"Forensic Sci Int"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-200808000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:34:02Z","timestamp":1738978442000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-200808000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31817ef470","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}